Ligand Pharmaceuticals Says On Feb 4 Entered Into  Worldwide Commercial Platform License Agreement With Genagon Therapeutics; Genagon Gained Access To Full Omniab Transgenic Animal Technology Platform;  Ligand Eligible To Receive Milestone Payments, Tiered Royalties Of 4%-6% For Each Product Incorporating Omniab-derived Antibody